Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Afatinib Shows Safety and Efficacy Among Elderly

Key clinical point: Afatinib appears safe and effective for elderly patients with non–small cell lung cancer.

Major finding: Elderly patients had 12-month progression-free survival rate of 62%.

Study details: A retrospective analysis of the GIDEON phase 3 trial.

Disclosures: Boehringer Ingelheim funded the study. The investigators did not report conflicts of interest.

Citation:

Brückl et al. ELCC 2019. Abstract 125P.